BTIG Maintains Buy Rating on Cullinan Therapeutics, Keeps $41 Target
BTIG maintained its Buy rating and $41 price target on Cullinan Therapeutics. The target implies 176.3% upside from the stock’s Oct. 27 close of $14.84.
Story updates
10:05:15 AM UTC
SquawkNews
Ratings actions from Benzinga: GMT) Cullinan Therapeutics Price Target Raised to $41.00/Share From $40.00 by BTIGRatings actions from Benzinga